



**Have you ever  
had a heart  
attack or stroke?**

**Do you have  
poor circulation?**

## Have you considered participating in a clinical study?

**Participating in this clinical study has the potential to improve future treatment options for people living with cardiovascular disease.**

### What is the REDEFINE 3 study?

REDEFINE 3 is looking at the combination of cagrilintide and semaglutide (CagriSema), which has the potential to impact cardiovascular risk factors. REDEFINE 3 is needed to help us understand the safety and potential benefits of CagriSema on the cardiovascular system.

### What are the BENEFITS for you?

- Expert medical care and education from a dedicated team of doctors and nurses
- Study-related care, including regular health check-ups
- Helping others by contributing to medical research

### You may qualify to participate if:

- You have had a stroke, a heart attack (myocardial infarction), or have poor circulation (peripheral arterial disease)
- You are 55 years of age or older
- You are living with overweight or obesity (BMI  $\geq$  25 kg/m<sup>2</sup>)
- You can have type 2 diabetes and/or chronic kidney disease
- You are able to attend regular clinic visits and receive phone calls over a period of 2.5 – 4.5 years, depending on when you start with the study



### This study is currently recruiting – please contact:

Cesar Ochoa/Research Coordinator - [cochoa@westernu.edu](mailto:cochoa@westernu.edu)  
Airani Sathananthan/Physician - [asathananthan@westernu.edu](mailto:asathananthan@westernu.edu)  
(909) 469-8626

**REDEFINE3**

cagrilintide and  
semaglutide  
combination

assessing  
cardiovascular  
outcomes and safety

Trial-ID: NN9838-4942  
Global English Master, Version 2.0,  
Date: 15-Sep-2023

